On November 19, 2025, Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Code: 688321.SH) announced the official launch of a collaboration with Beijing StoneWise Technology Co., Ltd. The partnership is centered on StoneWise's MolVado platform for 3D molecule generation and small-molecule drug design. Under this collaboration, StoneWise will provide Chipscreen with an engineered AI solution comprising a molecular generation model, a suite of AI-aided drug design (AIDD) computational validation tools, and a computational infrastructure. This integrated offering is designed to support Chipscreen's exploration and optimization efforts during the small-molecule drug research and development phase.

As a pioneer in China's original new drug arena, Chipscreen Biosciences has assembled a team of top-tier scientists with profound expertise in relevant fields. Leveraging its integrated technology platform that combines AI-assisted design and chemogenomics, the company has successfully developed two first-in-class and best-in-class original drugs: Chidamide (Epidaza®) and Chiglitazar Sodium (Bilessglu®). These drugs are commercially available globally for multiple indications. Furthermore, Chipscreen has established a portfolio of R&D projects with differentiated advantages and global competitiveness across various therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, and neurodegenerative diseases. The initiation of this collaboration represents a strategic exploration by both parties in the digital R&D toolchain.

Dr. Pan Desi, Vice President and Chief Scientific Officer of Chipscreen Biosciences, stated: Chipscreen Biosciences consistently adheres to the R&D philosophy centered on high-quality innovation and continuously explores technologies and solutions that can enhance the efficiency of drug discovery. This collaboration with StoneWise introduces their high-performance AI molecular generation models and systematic computational validation capabilities into our early-stage R&D process. We believe this will further improve the efficiency and precision of our early drug discovery efforts. We look forward to driving sustained breakthroughs in drug R&D by complementing each other's strengths.

Zhou Jielong, CEO of StoneWise, commented: Chipscreen Biosciences possesses profound drug R&D capabilities and is also one of the earliest domestic pioneers to recognize and implement AI in early-stage R&D activities. We are delighted to join hands with such a forward-thinking partner. Through this collaboration, StoneWise's MolVado platform will be more deeply integrated into real-world R&D scenarios. We aim to leverage our engineered, deliverable, and integrated platform capabilities to provide our partners with an efficient and controllable AI Co-pilot for drug R&D, jointly promoting the sustained and robust integration of AI into the drug discovery process.